EDTA Chelation Therapy:
Efficacy in Arteriosclerotic Heart Disease

H. Richard Casdorph, MD, PhD

Assistant Clinical Professor of Medicine at the University of 
California Medical School, Irvine California

ABSTRACT: Eighteen patients with documented arteriosclerotic heart disease were studied utilizing the isotope technetium 99m to measure left ventricular ejection fraction before and after the administration of EDTA chelation therapy. A statistically significant improvement in left ventricular ejection fraction occurred in this group of patients.

TABLE 1:

Ejection Fraction Measured by Technetium 99m Before and
After Chelation Therapy*

Patient	Age	Sex	Before	After	Change*	# Treatments
1.  RH	59	M	51%	62%	+11%	20
2.  RS	65	M	35%	40%	+  5%	20
3.  ES	54	M	55%	71%	+16%	20
4.  MW	72	F	59%	61%	+  2%	20
5.  GB	75	F	74%	77%	+  3%	20
6.  SW	45	M	53%	65%	+ 12%	20
7.  HH	72	F	59%	69%	+ 10%	18
8.  MB	73	F	46%	61%	+ 15%	20
9.  DF	60	F	61%	68%	+  7%	4
10. KS	57	F	76%	77%	+  1%	20
11. MC	57	F	73%	79%	+  6%	20
12. UG	72	F	63%	64%	+  1%	16
13. ND	67	M	63%	66%	+  3%	20
14. CA	56	M	64%	65%	+  1%	20
15. AA	55	F	65%	68%	+  3%	20
16. RP	48	F	58%	56%	-  2%	20
17. AC	52	M	58%	61%	+  3%	20
18. JR	47	M	63%	70%	+  7%	20

Mean Change + 5.77%
Range - 2 to + 16% (P < 0.0005)

*Studies performed at Nuclear Medicine Department Long Beach Community Hospital using 20 millicuries technetium 99m glucoheptonate. Unless otherwise indicated, treatment consisted of 20 IV infusions of 3 gm EDTA.

Copyright © 2007 MedTech Consulting. Inc., all rights reserved

Last modified: